Dextroamphetamine vs Amphetamine Salts: Key Differences
Dextroamphetamine and mixed amphetamine salts (Adderall) are both highly effective first-line treatments for ADHD and narcolepsy with comparable efficacy, but mixed amphetamine salts may offer superior retention in treatment. 1
Composition and Formulation
Dextroamphetamine is a single-isomer formulation containing only the dextro (right-handed) enantiomer of amphetamine 2, 3
Mixed amphetamine salts (Adderall) contain a 3:1 ratio of dextroamphetamine to levoamphetamine, specifically: dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate 4
Both medications are DEA Schedule II controlled substances with high potential for abuse 5
Clinical Efficacy
A Cochrane systematic review found that all three amphetamine derivatives (dextroamphetamine, lisdexamfetamine, and mixed amphetamine salts) significantly improved ADHD symptom severity with a standardized mean difference of -0.72 (95% CI -0.87 to -0.57) 1
Mixed amphetamine salts demonstrated a unique advantage in increasing retention in treatment compared to dextroamphetamine alone, though the mechanism for this difference is unclear 1
In adults with ADHD, mixed amphetamine salts at an average dose of 54 mg daily (administered in two divided doses) produced a 42% decrease in ADHD Rating Scale scores (P<0.001), with 70% of subjects achieving clinically meaningful improvement (≥30% reduction) versus 7% with placebo 4
For narcolepsy, dextroamphetamine 30 mg daily was only slightly more potent than 10 mg daily in reducing attack frequency, with both doses roughly halving the reported frequency of narcoleptic attacks 6
Dosing Considerations
For ADHD:
Dextroamphetamine: Start with 5 mg once or twice daily in patients ≥6 years; titrate by 5 mg weekly intervals until optimal response; rarely necessary to exceed 40 mg/day total 2
Mixed amphetamine salts: Start with 10 mg once daily in the morning for adults; titrate by 5 mg weekly based on response and tolerability; maximum recommended daily dose is 50 mg for adults 7
For Narcolepsy:
- Both medications: Usual dose range is 5-60 mg per day in divided doses 2
- For patients aged 6-12 years: Start with 5 mg daily; increase by 5 mg weekly 2
- For patients ≥12 years: Start with 10 mg daily; increase by 10 mg weekly 2
Pharmacokinetic Profiles
Immediate-release formulations of both medications provide 4-6 hours of clinical action, requiring multiple daily doses (typically given on awakening with additional doses at 4-6 hour intervals) 8, 2
Extended-release mixed amphetamine salts (Adderall XR) provide approximately 8-9 hours of symptom control 9
Dextroamphetamine extended-release (Dexedrine Spansules) similarly provides 8-9 hours of coverage 9
Most patients could not distinguish subjective effects between immediate-release dextroamphetamine tablets and extended-release Spansules 6
Side Effect Profile
Both medications share similar sympathomimetic side effects including hyperactivity, hyperthermia, tachycardia, tachypnea, mydriasis, tremors, and potential seizures in overdose 5
Appetite suppression is more commonly reported with mixed amphetamine salts compared to other ADHD medications 10
Amphetamines as a class were associated with significantly higher dropout rates due to adverse events (RR 3.03; 95% CI 1.52 to 6.05) compared to placebo 1
Cardiovascular monitoring (blood pressure and pulse) is required at baseline and regularly during treatment with both medications 10, 7
Clinical Decision-Making Algorithm
When choosing between these medications:
Start with mixed amphetamine salts (Adderall) if treatment retention is a concern, as this formulation has demonstrated superior adherence in clinical trials 1
Consider dextroamphetamine if the patient has previously responded well to single-isomer formulations or if cost is a significant barrier (generic dextroamphetamine may be less expensive) 2
Use extended-release formulations (Adderall XR or Dexedrine Spansules) for once-daily dosing to improve adherence and reduce stigma associated with in-school dosing 10, 9
If inadequate response occurs after adequate treatment with one amphetamine formulation, approximately 40% of patients respond to both methylphenidate and amphetamines, while 40% respond to only one class—trial the other stimulant class (methylphenidate) before abandoning stimulants entirely 10
Common Pitfalls to Avoid
Do not assume higher doses are always better: More than 70% of patients respond when a full range of doses is properly titrated, but excessive dosing can paradoxically worsen attention and cause overstimulation 7
Avoid late evening doses of either medication due to resulting insomnia 2
Do not use with MAO inhibitors due to risk of severe hypertension and potential cerebrovascular accidents; allow at least 14 days between discontinuation of an MAOI and initiation of amphetamines 10
Exercise caution in patients with substance abuse disorders: Consider long-acting formulations with lower abuse potential or non-stimulant alternatives like atomoxetine 10